NO20052646L - Method of treating cognitive decline due to sleep deprivation and stress - Google Patents
Method of treating cognitive decline due to sleep deprivation and stressInfo
- Publication number
- NO20052646L NO20052646L NO20052646A NO20052646A NO20052646L NO 20052646 L NO20052646 L NO 20052646L NO 20052646 A NO20052646 A NO 20052646A NO 20052646 A NO20052646 A NO 20052646A NO 20052646 L NO20052646 L NO 20052646L
- Authority
- NO
- Norway
- Prior art keywords
- stress
- cognitive decline
- sleep deprivation
- treating cognitive
- decline due
- Prior art date
Links
- 208000010877 cognitive disease Diseases 0.000 title abstract 2
- 208000010340 Sleep Deprivation Diseases 0.000 title 1
- 230000006999 cognitive decline Effects 0.000 title 1
- 102000003678 AMPA Receptors Human genes 0.000 abstract 1
- 108090000078 AMPA Receptors Proteins 0.000 abstract 1
- 208000028698 Cognitive impairment Diseases 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 230000006399 behavior Effects 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 206010022437 insomnia Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 210000000225 synapse Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43973503P | 2003-01-13 | 2003-01-13 | |
| PCT/US2004/000706 WO2004062616A2 (en) | 2003-01-13 | 2004-01-13 | Method of treating cognitive decline due to sleep deprivation and stress |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20052646D0 NO20052646D0 (no) | 2005-06-02 |
| NO20052646L true NO20052646L (no) | 2005-08-11 |
Family
ID=32713510
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20052646A NO20052646L (no) | 2003-01-13 | 2005-06-02 | Method of treating cognitive decline due to sleep deprivation and stress |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20060276462A1 (pl) |
| EP (1) | EP1592464A4 (pl) |
| JP (1) | JP2006516283A (pl) |
| KR (1) | KR20050094840A (pl) |
| CN (1) | CN1764460A (pl) |
| AU (1) | AU2004204814B2 (pl) |
| BR (1) | BRPI0406736A (pl) |
| CA (1) | CA2509251A1 (pl) |
| EA (1) | EA200501117A1 (pl) |
| MX (1) | MXPA05007389A (pl) |
| NO (1) | NO20052646L (pl) |
| NZ (1) | NZ540468A (pl) |
| PL (1) | PL378366A1 (pl) |
| UA (1) | UA80317C2 (pl) |
| WO (1) | WO2004062616A2 (pl) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050215889A1 (en) * | 2004-03-29 | 2005-09-29 | The Board of Supervisory of Louisiana State University | Methods for using pet measured metabolism to determine cognitive impairment |
| US20090286797A1 (en) * | 2005-11-22 | 2009-11-19 | Dan Peters | Novel Quinoxaline Derivatives and Their Medical Use |
| BRPI0716375A2 (pt) * | 2006-08-31 | 2013-10-15 | Univ Alberta | Método para reduzir ou inibir depressão respiratória em um sujeito; método para induzir analgesia, anestesia ou sedação em um sujeito, reduzindo ou inibindo simultaneamente depressão respiratória no sujeito; e composição farmacêutica para induzir analgesia, anestesia ou sedação em um sujeito... |
| ZA200904826B (en) * | 2007-01-03 | 2010-09-29 | Cortex Pharma Inc | 3-substituted-[1,2,3]-benzotriazinone compound for enhancing glutamatergic synaptic responses |
| CA2731657A1 (en) * | 2008-07-28 | 2010-02-04 | Nihon Medi-Physics Co., Ltd. | Technique for detecting neurodegenerative disorders |
| HUE034911T2 (hu) | 2009-07-27 | 2018-03-28 | Gilead Sciences Inc | Fúzionált heterociklusos vegyületek mint ioncsatorna modulátorok |
| US20110257186A1 (en) * | 2010-04-15 | 2011-10-20 | Staubli Ursula V | Compositions and methods for treating visual disorders |
| EP2588197B1 (en) | 2010-07-02 | 2014-11-05 | Gilead Sciences, Inc. | Fused heterocyclic compounds as ion channel modulators |
| WO2012154760A1 (en) | 2011-05-10 | 2012-11-15 | Gilead Sciences, Inc. | Fused heterocyclic compounds as sodium channel modulators |
| UY34171A (es) | 2011-07-01 | 2013-01-31 | Gilead Sciences Inc | Compuestos heterocíclicos fusionados como moduladores del canal iónico |
| NO3175985T3 (pl) | 2011-07-01 | 2018-04-28 | ||
| US10555916B2 (en) | 2013-01-25 | 2020-02-11 | Case Western Reserve University | NMDAR antagonist for the treatment of pervasive development disorders |
| US9857971B2 (en) * | 2013-12-02 | 2018-01-02 | Industrial Technology Research Institute | System and method for receiving user input and program storage medium thereof |
| JP7444727B2 (ja) | 2020-08-05 | 2024-03-06 | 株式会社 資生堂 | 感触評価方法および感触評価装置 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69331761T2 (de) | 1992-07-24 | 2002-09-12 | The Regents Of The University Of California, Oakland | Arzneimittel, die den durch ampa rezeptoren vermittelten synaptischen respons erhöhen |
| US5852008A (en) | 1995-01-24 | 1998-12-22 | The Regents Of The University Of California | Heteroatom substituted benzoyl derivatives that enhance synaptic response mediated by receptors |
| US5650409A (en) | 1995-06-02 | 1997-07-22 | Cortex Pharmaceuticals, Inc. | Benzoyl piperidines/pyrrolidines for enhancing synaptic response |
| US5891871A (en) | 1996-03-21 | 1999-04-06 | Cocensys, Inc. | Substituted 2,3-benzodiazepin-4-ones and the use thereof |
| US5736543A (en) | 1996-04-03 | 1998-04-07 | The Regents Of The University Of California | Benzoxazines for enhancing synaptic response |
| US6110935A (en) * | 1997-02-13 | 2000-08-29 | The Regents Of The University Of California | Benzofurazan compounds for enhancing glutamatergic synaptic responses |
| US6166008A (en) * | 1997-10-27 | 2000-12-26 | Cortex Pharmaceuticals, Inc. | Treatment of schizophrenia with ampakines and neuroleptics |
| US5985871A (en) | 1997-12-24 | 1999-11-16 | Cortex Pharmaceuticals, Inc. | Benzoxazine compounds for enhancing synaptic response |
| ATE556710T1 (de) * | 2004-01-26 | 2012-05-15 | Cortex Pharma Inc | Verbesserung der durch ampakine induzierten erleichterung von synaptischen reaktionen durch cholinesterase-inhibitoren |
-
2004
- 2004-01-13 PL PL378366A patent/PL378366A1/pl not_active Application Discontinuation
- 2004-01-13 NZ NZ540468A patent/NZ540468A/en unknown
- 2004-01-13 CN CNA2004800021731A patent/CN1764460A/zh active Pending
- 2004-01-13 BR BR0406736-3A patent/BRPI0406736A/pt not_active IP Right Cessation
- 2004-01-13 AU AU2004204814A patent/AU2004204814B2/en not_active Ceased
- 2004-01-13 EP EP04701787A patent/EP1592464A4/en not_active Withdrawn
- 2004-01-13 MX MXPA05007389A patent/MXPA05007389A/es active IP Right Grant
- 2004-01-13 KR KR1020057012912A patent/KR20050094840A/ko not_active Ceased
- 2004-01-13 WO PCT/US2004/000706 patent/WO2004062616A2/en not_active Ceased
- 2004-01-13 JP JP2006500909A patent/JP2006516283A/ja active Pending
- 2004-01-13 EA EA200501117A patent/EA200501117A1/ru unknown
- 2004-01-13 US US10/541,687 patent/US20060276462A1/en not_active Abandoned
- 2004-01-13 CA CA002509251A patent/CA2509251A1/en not_active Abandoned
- 2004-01-13 UA UAA200508006A patent/UA80317C2/uk unknown
-
2005
- 2005-06-02 NO NO20052646A patent/NO20052646L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EA200501117A1 (ru) | 2006-02-24 |
| MXPA05007389A (es) | 2006-02-10 |
| KR20050094840A (ko) | 2005-09-28 |
| CA2509251A1 (en) | 2004-07-29 |
| NO20052646D0 (no) | 2005-06-02 |
| PL378366A1 (pl) | 2006-04-03 |
| NZ540468A (en) | 2008-03-28 |
| WO2004062616A3 (en) | 2005-12-15 |
| EP1592464A2 (en) | 2005-11-09 |
| CN1764460A (zh) | 2006-04-26 |
| WO2004062616A2 (en) | 2004-07-29 |
| AU2004204814B2 (en) | 2009-10-08 |
| EP1592464A4 (en) | 2011-03-09 |
| AU2004204814A1 (en) | 2004-07-29 |
| US20060276462A1 (en) | 2006-12-07 |
| UA80317C2 (en) | 2007-09-10 |
| BRPI0406736A (pt) | 2005-12-20 |
| JP2006516283A (ja) | 2006-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2021252538A3 (en) | Advantageous benzofuran compositions for mental disorders or enhancement | |
| SG169224A1 (en) | Method for treatment of tumors using nordihydrogualaretic acid derivatives | |
| MX2025005941A (es) | Moduladores de la actividad tnf-\03b1 | |
| NO20081975L (no) | Diarylamin-inneholdende forbindelser og sammensetninger, og deres anvendelse som modulatorer av C-kit-reseptorer | |
| NO20074999L (no) | Metode og preparat for behandling av perifere vaskulaere sykdommer | |
| AR043188A1 (es) | Metodos y composiciones para el tratamiento de enfermedades y trastornos asociados con niveles elevados de citoquinas proinflamatorias | |
| NO20081838L (no) | 5-lipoksygenaseaktiverende protein-(FLAP)-inhibitorer | |
| BRPI0507198A (pt) | derivados de bisariluréia | |
| NO20082643L (no) | Isokinolinaminopyrazolderivater, deres fremstilling og anvendelse som farmasoytiske midler for behandling av kreft | |
| NO20012896L (no) | Fremgangsmåte for behandling av cerebral ischemi og anvendelse av erytropoietin eller erytropoietinderivater forbehandling av cerebral ischemi | |
| WO2006023702A3 (en) | Method for treating sleep related breathing disorders with setiptiline | |
| MXPA05007389A (es) | Metodo para el tratamiento de la deficiencia cognitiva debido a la privacion de sueno y estres. | |
| BRPI0408863A (pt) | composto, composição farmacêutica, método para tratar doenças, e, uso de um composto. | |
| WO2025024305A3 (en) | Irak4 degraders and uses thereof | |
| AR049518A1 (es) | Composicion farmaceutica que comprende un agente siliconado y dos principios activos solubilizados | |
| WO2006098603A3 (en) | Composition comprising isoorientin for suppressing histamine | |
| BR0308957A (pt) | Composto, composição farmacêutica, método para o tratamento de uma inflamação ou de uma desordem associada a uma inflamação em um paciente, uso dos compostos e processo para sua preparação | |
| MX2021011289A (es) | Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas. | |
| NO20064964L (no) | Behandling av svekket respiratorisk funksjon | |
| DE602007010734D1 (de) | Hydratformen von amg706 | |
| NO20075562L (no) | Anvendelse av selektive klorid kanal modulatorer for behandling av alkohol og/eller medikament misbruk | |
| WO2009131850A3 (en) | Pai-1 expression and activity inhibitors for the treatment of ocular disorders | |
| AR054435A1 (es) | Agente para profilaxis o terapia contra la depresion o desorden de ansiedad | |
| WO2024197216A3 (en) | Mdm2 degraders and uses thereof | |
| NO20091659L (no) | Fremgangsmater for behandling av disruptive oppforselsforstyrrelser |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |